A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial

Liposomal daunorubicin and cytarabine (CPX-351) improved overall survival (OS) compared with 7+3 chemotherapy in older patients with secondary acute myeloid leukemia (AML); to date, there have been no randomized studies in younger patients. The high-risk cohort of the UK NCRI AML19 trial (ISRCTN7844...

Descripción completa

Detalles Bibliográficos
Autores principales: Othman, Jad, Wilhelm-Benartzi, Charlotte, Dillon, Richard, Knapper, Steve, Freeman, Sylvie D., Batten, Leona M., Canham, Joanna, Hinson, Emily L., Wych, Julie, Betteridge, Sophie, Villiers, William, Kleeman, Michelle, Gilkes, Amanda, Potter, Nicola, Overgaard, Ulrik Malthe, Mehta, Priyanka, Kottaridis, Panagiotis, Cavenagh, Jamie, Hemmaway, Claire, Arnold, Claire, Dennis, Mike, Russell, Nigel H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425682/
https://www.ncbi.nlm.nih.gov/pubmed/37171402
http://dx.doi.org/10.1182/bloodadvances.2023010276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425682/
https://www.ncbi.nlm.nih.gov/pubmed/37171402
http://dx.doi.org/10.1182/bloodadvances.2023010276

Ejemplares similares